IntelGenx Technologies Corp. (IGXT)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Tommy Kenny J.D., L.L.B., M.Sc. | Senior VP & General Counsel | 152.62k | -- | 1987 |
| Ms. Nadine Paiement M.Sc. | Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp | 156.5k | -- | 1977 |
| Ms. Karen Kalayajian CPA | Vice President of Finance & Administration | -- | -- | 1980 |
| Stephen Kilmer | Investor Relations Officer | -- | -- | -- |
| Zenoz Nina Pourhassan | VP of Quality Operations of Subsidiary | -- | -- | -- |
IntelGenx Technologies Corp.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer and Parkinsons; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also develops INT0039/2013 for pain; and INT0053/2020 for the treatment of resistant depression. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
July 8, 2024 at 12:00 AM UTC
POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing